AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19025528
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl in ropivacaine (0.1 mcg/kg/ml fentanyl in 1.5 mg/ml ropivacaine, infused at 2 ml/h)
Trial: 12860494
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 mg administered at -5 or -10 minutes relative to food
Trial: 12860494
Drug: Nateglinide 60
RxNorm normalized name: nateglinide 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 60 mg administered at -30 or -10 minutes
Trial: 10371365
Drug: Sampatrilat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sampatrilat (50 to 100 mg daily)
Trial: 10371365
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 to 20 mg daily)
Trial: 8904562
Drug: Ibuprofen (Ibu;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (Ibu; 1,200 mg/day)
Trial: 1990938
Drug: M6 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M6 regimen (6 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Trial: 1990938
Drug: M8 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M8 regimen (8 months of treatment with streptomycin, isoniazid, rifampin, and pyrazinamide)
Trial: 6523889
Drug: Chemotherapy (B)
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (B) and chemoimmunotherapy (C)
Trial: 30994287
Drug: 8-time application,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-time application, each time 750 mL per plant (F1)
Trial: 30994287
Drug: 12-time application,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-time application, each time 500 mL per plant (F2)
Trial: 30994287
Drug: 16-time application,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16-time application, each time 375 mL per plant (F3)
Trial: 30994287
Drug: Irrigating by
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irrigating by 120% daily evapotranspiration (ET) before fruit enlargement, by 140%ET after fruit enlargement (W1)
Trial: 30994287
Drug: F3W1 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: F3W1 treatment (16-time application with 120% ET before and 140% ET after)
Trial: 30134291
Drug: Viral load
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viral load suppression to less than 50 copies/ml
Trial: 25176628
Drug: Midazolam administered
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam administered by cardiologist only
Trial: 19947260
Drug: Medication acupoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication acupoint sticking therapy (using cakes made of grinding pepper, brassica alba seeds, asarum, mixed with ginger oil and ginger juice)
Trial: 17936213
Drug: Best available
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Best available treatments
Trial: 15199394
Drug: Prophylactic radiotherapy
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic radiotherapy with a single 10-Gy treatment using 9-MeV electrons
Trial: 2752557
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg s.l.)
Trial: 50181
Drug: Alcohol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (mean blood alcohol content of 90 mg%)
Trial: 30295400
Drug: Morphine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (30 mg, subcutaneous, four-times daily) with naloxone (0.4 mg, IM) challenge
Trial: 30295400
Drug: Clonidine, tramadol-ER,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine, tramadol-ER, and buprenorphine (RCT medications)
Trial: 3657889
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of aspartame per kilogram of body weight
Trial: 29902133
Drug: MMR-RIT vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR-RIT vaccine (Priorix, GSK)
Trial: 29902133
Drug: MMR II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR II vaccine (control; M-M-R II, Merck&Co Inc.)
Trial: 21062996
Drug: Serp-1 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serp-1 (5 μg/kg)
Trial: 21062996
Drug: Serp-1 (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serp-1 (15 μg/kg)
Trial: 18187530
Drug: MK-0343 0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0343 0.75 mg
Trial: 18187530
Drug: MK-0343 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0343 0.25 mg
Trial: 14732977
Drug: PVP chemotherapy
RxNorm normalized name: PVP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PVP chemotherapy
Trial: 9014295
Drug: DHEAS, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEAS, 50 mg po bid for 4 days, administered as an adjuvant to tetanus vaccination.
Trial: 9014295
Drug: DHEAS administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEAS administered immediately before and 24 hours after influenza vaccination.
Trial: 1362613
Drug: Cysteine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cysteine (200 mg 4 times daily)
Trial: 1362613
Drug: MMSC (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMSC (500 mg 4 times daily)
Trial: 1362613
Drug: Sulphasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (2 g daily) and Cysteine
Trial: 1362613
Drug: Sulphasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (2 g daily) and MMSC
Trial: 1362613
Drug: Sulphasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (2 g daily) alone
Trial: 3161176
Drug: 0.3% foscarnet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% foscarnet cream
Trial: 20702806
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BR; 0.5 l/day; 5.2 mmol of NO(3)(‐)/day)
Trial: 18469091
Drug: Esomeprazole (ESO)
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Esomeprazole (ESO) 20 mg once daily (can be increased to 40 mg once daily or 20 mg twice daily)
Trial: 12014516
Drug: 2 IU/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 IU/m2/day of growth hormone (GH)
Trial: 12014516
Drug: 4 IU/m2/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 IU/m2/day of growth hormone (GH)
Trial: 12014516
Drug: Low-dose group
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose group (2 IU/m2/day)
Trial: 12014516
Drug: High-dose group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose group (4 IU/m2/day)
Trial: 10081129
Drug: Sublingual glycine
RxNorm normalized name: Glycine
DrugBank: Glycine (DB00145)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual glycine application in daily dose of 1-2 g for 5 days, starting within the first 6 hours of stroke development.
Trial: 7583388
Drug: Cessation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cessation of antibiotics regardless of ANC; initial treatment with ceftazidime +/- vancomycin for a median length of treatment of 3 days
Trial: 31064965
Drug: Daily life-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily life-based physical activity enhancement program with one-on-one counseling, customized text messages, exercise diary, and mobile pedometer for 12 weeks
Trial: 19303137
Drug: Imatinib 400
RxNorm normalized name: imatinib 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib 400 mg daily for 1 year
Trial: 8647360
Drug: Oral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral etoposide (n = 18)
Trial: 8647360
Drug: Parenteral etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Parenteral etoposide (n = 18)
Trial: 1596044
Drug: Doxycycline-rifampin (DR)
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline-rifampin (DR) combination therapy
Trial: 1596044
Drug: Doxycycline-streptomycin (DS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline-streptomycin (DS) combination therapy
Trial: 1596044
Drug: Doxycycline-rifampin (DR)
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline-rifampin (DR) combination therapy excluding spondylitis patients
Trial: 1596044
Drug: Doxycycline-streptomycin (DS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline-streptomycin (DS) combination therapy excluding spondylitis patients
Trial: 6208807
Drug: 5% plasmaprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% plasmaprotein solution (PPS)
Trial: 20189927
Drug: Concord grape
RxNorm normalized name: Concord Grape
DrugBank: Concord grape (DB10875)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concord grape juice (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Trial: 20189927
Drug: Placebo (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4 oz. prior to meals for one week following each of four chemotherapy treatment cycles)
Trial: 18758386
Drug: Trimethoprim-sulfamethoxazole 18
RxNorm normalized name: sulfamethoxazole / trimethoprim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole 18 mg/kg twice daily
Trial: 16190387
Drug: Ulinastatin 1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin 1.2 x 10(4) U/kg (half dose intravenously after induction, half in primary solution)
Trial: 12208645
Drug: Sustained-release ascorbic
RxNorm normalized name: ascorbic acid Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release ascorbic acid (3000 mg/day)
Trial: 25980582
Drug: Daily tailored
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily tailored text messaging for 90 days
Trial: 22441104
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment group (ITG) with Peg IFNa-2a and ADV
Trial: 22441104
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (STG) with Peg IFNa-2a monotherapy
Trial: 22441104
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment group (ITG)
Trial: 25100538
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment group (STG)
Trial: 15855501
Drug: Alamifovir single
RxNorm normalized name: Alamifovir
DrugBank: Alamifovir (DB06368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alamifovir single doses (0.2 to 80 mg), subset receiving 20 mg in a fed state
Trial: 15855501
Drug: Alamifovir multiple
RxNorm normalized name: Alamifovir
DrugBank: Alamifovir (DB06368)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alamifovir multiple doses (2.5 to 15 mg twice daily for 15 days)
Trial: 8951781
Drug: Non radio-mimetic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non radio-mimetic agents (hydroxyurea or pipobroman)
Trial: 8951781
Drug: Non radio-mimetic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non radio-mimetic agents (hydroxyurea or pipobroman) in relatively young cases
Trial: 1937996
Drug: Ciprofloxacin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (200 mg) given i.v. 1, 2 and 3 h before surgery
Trial: 21378581
Drug: Castile soap
RxNorm normalized name: CASTILE SOAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Castile soap solution
Trial: 9430592
Drug: Implications for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implications for treatment development
Trial: 2818278
Drug: Topical timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topical timolol therapy (twice daily)
Trial: 27812689
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and cyclophosphamide followed by paclitaxel with the addition of 1 year of weekly trastuzumab (ACTH)
Trial: 23222289
Drug: Loperamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (4 mg, 2 capsules)
Trial: 21631929
Drug: Roflumilast (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast (500 μg tablet once daily; Day 2-18) and concomitant formoterol (24 μg twice daily; Day 12-18)
Trial: 21631929
Drug: Formoterol (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (24 μg twice daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18)
Trial: 21631929
Drug: Roflumilast and
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast and formoterol administered concomitantly
Trial: 21631929
Drug: Roflumilast and
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast and formoterol administered individually
Trial: 19459520
Drug: ARB (Telmisartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (Telmisartan 80 mg/day)
Trial: 19459520
Drug: Control (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (ACE inhibitors only, Enalapril 40 mg/day)
Trial: 8038358
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg t.d.s. plus tetracycline 500 mg q.d.s. for 14 days (OMP/TCN)
Trial: 8038358
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg in the morning plus tetracycline 500 mg q.d.s. along with bismuth subsalicylate tablets 2 q.d.s. for 14 days (OMP/TCN/BSS)
Trial: 3055941
Drug: Tri-buffered aspirin
RxNorm normalized name: Tri-Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tri-buffered aspirin
Trial: 31134713
Drug: Concurrent Cogmed
RxNorm normalized name: SUCTION TUBE ATTACH DEVICE CONMED #34870
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent Cogmed and metacognitive strategy training
Trial: 28061873
Drug: Melatonin 4
RxNorm normalized name: vit B/folic acid/calcium/soy xt/black cohosh xt/melatonin 400 mcg-125 mg-62 mg-40 mg (day)/175 mg-62 mg-1 mg (night) ORAL CAPSULE, SEQUENTIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 4 mg enterally administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Trial: 28061873
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered once per day at 21:00 until ICU discharge or 14 days after enrolment, whichever occurs first.
Trial: 17048435
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg DEC plus 400 mg ABZ
Trial: 17048435
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg DEC alone
Trial: 12663845
Drug: Stimulant users
RxNorm normalized name: Staphylococcus simulans
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant users (cocaine or amphetamines)
Trial: 10492061
Drug: Atovaquone-proguanil (1000/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone-proguanil (1000/400 mg) with artesunate (250 mg)
Trial: 10492061
Drug: Atovaquone-proguanil (1000/400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atovaquone-proguanil (1000/400 mg) without artesunate
Trial: 8909421
Drug: Weekly low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly low-dose oral methotrexate
Trial: 2275513
Drug: Low-dosage oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dosage oral contraceptives
Trial: 29160424
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard physical therapy without non-invasive ventilation)
Trial: 22316073
Drug: Zinc (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc (20 mg for children ≥ 12 months, and 10 mg for those < 12 months) once daily for seven days
Trial: 22316073
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for seven days
Trial: 17984834
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + Daclizumab (steroid-free)
Trial: 17984834
Drug: Tacrolimus +
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus + Mycophenolate Mofetil (MMF) + Daclizumab (steroid-free)
Trial: 14627912
Drug: Steroid-free protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid-free protocol
Trial: 10371880
Drug: NUPRO Gold
RxNorm normalized name: Nupro Chlorhexidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUPRO Gold active gel
Trial: 10371880
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel without the active agent
Trial: 7631676
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation for 3 weeks
Trial: 30835574
Drug: Hormonal oral
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal oral contraceptive use
Trial: 28874181
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein and low glycemic index diet (1.3-1.4 g/kg/day)
Trial: 25914962
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with interval debulking (NACT‐IDS)
Trial: 21170734
Drug: 3,000 mg
RxNorm normalized name: ascorbic acid/minerals 3,000 mg ORAL POWDER IN PACKET (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3,000 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Trial: 21170734
Drug: 700 mg
RxNorm normalized name: cystine 700 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 700 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Trial: 21170734
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg l⁻¹ clove solution for 40, 120, and 240 s exposure
Trial: 19008771
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment (given to 69% of children)
Trial: 19770794
Drug: Simvastatin (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (lower than therapeutically equivalent dose)
Trial: 19770794
Drug: Simvastatin (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (not prescribed a higher milligram dose)
Trial: 19770794
Drug: Atorvastatin (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (control group)
Trial: 8148290
Drug: Epinephrine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epinephrine (5 micrograms/mL)
Trial: 30020510
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab with pertuzumab
Trial: 30020510
Drug: Chemotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy plus trastuzumab without pertuzumab
Trial: 22016458
Drug: Nonoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative treatment (immobilization and physiotherapy)
Trial: 18067679
Drug: Intermittent preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent preventive treatment with sulphadoxine‐pyrimethamine (SP)
Trial: 11449082
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined oral HRT (2 mg of estradiol plus 1 mg of norethisterone acetate)
Trial: 28025442
Drug: 1% Matricaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Matricaria chamomilla L. mouthwash
Trial: 25668505
Drug: Topical β-glucan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical β-glucan
Trial: 13678479
Drug: Clarithromycin ER
RxNorm normalized name: Clarithromycin ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin ER 500 mg once daily for 5 days
Trial: 13678479
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 500 mg three times daily for 10 days
Trial: 10490554
Drug: Thrombolytic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic treatment with alteplase
Trial: 8739554
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg daily for 16 days)
Trial: 8739554
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg, SC)
Trial: 6765541
Drug: 15:85% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15:85% human insulin mixture
Trial: 6765541
Drug: 10:90% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10:90% human insulin mixture
Trial: 6765541
Drug: 20:80% human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20:80% human insulin mixture
Trial: 6765541
Drug: 15:85% and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15:85% and 20:80% human insulin mixtures